In an effort to ascertain the expression pattern of FR-β in nonmyelogenous malignancies, we have exploited a recently developed monoclonal antibody to human FR-β [25] to stain nearly 1000 human tumor tissue sections from 20 different tumor types. The gene discussed is FOLR2; the disease is neoplasm.